"name","label","rationale","id","uuid:ID","description","instanceType"
"Study Design 1","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","c2a9d5c0-9e4e-47c2-8820-a5f5e12f0679","The main design for the study","StudyDesign"
